Windtree Reveals Encouraging Data From Istaroxime Study In Early Cardiogenic Shock

Windtree Therapeutics Inc WINT has announced positive primary results with istaroxime in rapidly raising systolic blood pressure.

Istaroxime is a first-in-class dual mechanism therapy designed to improve systolic and diastolic cardiac function. 

Windtree is advancing multiple late-stage interventions for acute cardiovascular and acute pulmonary disorders.

What Happened: The SEISMiC Phase 2 study enrolled 60 patients with early cardiogenic shock due to severe heart failure with systolic blood pressures (SBP) between 75-90 mmHg. 

Two istaroxime doses were evaluated, 1.5 µg/kg/min in the first group and 1.0 µg/kg/min in the next group. 

These groups were combined for analysis and compared to a placebo. 

The study met its primary endpoint in SBP profile over six hours, with the istaroxime treated group performing significantly better than the control group.

In response to Benzinga's question, "How does the announcement affect the company financially," Craig Fraser, CEO of Windtree, said, "as a small biotech, we are assessing our financing options and will carefully consider the best way to proceed. We are also engaged in business development which may be a source of non-dilutive support to advancing the programs."

Read Next: Windtree Posts Mid-Stage Study Data On Lucinactant For COVID-19-Associated Respiratory Distress.

Why It Matters: Cardiogenic shock is a condition that occurs when the heart is failing significantly and cannot pump enough blood and oxygen to the brain, kidneys, and other vital organs. 

Mortality rates are significant and, depending on severity, ranging from 7% to 40% in the U.S. 

Further details of the study results are planned to be presented at the European Society of Cardiology Heart Failure meeting to be held next month.

Price Action: WINT shares closed 1.52% higher at $1.00 on Tuesday.

Editor's Note: The post has been updated to include CEO comments.

Photo via Company website

Posted In: Phase 2 TrialBiotechNewsPenny StocksHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.